Preliminary study of selective estrogen modulators (SERMs) combined with maximum androgen blockade for metastatic prostate cancer

Trial Profile

Preliminary study of selective estrogen modulators (SERMs) combined with maximum androgen blockade for metastatic prostate cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Raloxifene (Primary) ; Toremifene (Primary) ; Antiandrogens
  • Indications Bone metastases; Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 01 Jan 2015 Status changed from recruiting to active, no longer recruiting, as per the results published in the BMC Cancer.
    • 29 Sep 2011 Status changed from not stated to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top